Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANGO AngioDynamics	$9.48 -1.7%	$9.86	$5.67 ▼ $13.50	$391.45M	0.6	581,653 shs	668,223 shs
INO Inovio Pharmaceuticals	$1.39 -4.1%	$1.95	$1.30 ▼ $12.33	$53.18M	1.31	802,729 shs	2.58 million shs
SIBN SiBone	$18.78 +1.8%	$18.17	$11.70 ▼ $20.05	$785.81M	0.93	392,035 shs	294,940 shs
SRDX Surmodics	$31.02 +0.6%	$28.96	$26.00 ▼ $42.25	$440.99M	1.31	221,719 shs	66,258 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANGO AngioDynamics	-1.66%	-1.15%	-14.90%	+2.05%	+69.29%
INO Inovio Pharmaceuticals	-4.14%	-3.14%	-38.22%	-13.66%	-85.02%
SIBN SiBone	+1.84%	+1.73%	-1.68%	+40.46%	+38.60%
SRDX Surmodics	+0.58%	+3.45%	+6.23%	+8.88%	-26.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANGO AngioDynamics	3.5207 of 5 stars	3.5	1.0	4.2	0.0	1.7	0.6
INO Inovio Pharmaceuticals	3.899 of 5 stars	3.3	1.0	4.4	2.9	0.0	1.3
SIBN SiBone	4.0478 of 5 stars	2.5	5.0	3.3	2.0	2.5	0.6
SRDX Surmodics	4.1985 of 5 stars	3.3	3.0	3.4	0.8	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANGO AngioDynamics	3.00	Buy	$14.00	47.68% Upside
INO Inovio Pharmaceuticals	2.60	Moderate Buy	$8.80	533.09% Upside
SIBN SiBone	3.00	Buy	$22.50	19.81% Upside
SRDX Surmodics	2.50	Moderate Buy	$43.00	38.62% Upside

Current Analyst Ratings Breakdown

Latest ANGO, SIBN, INO, and SRDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$5.00
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
5/6/2025	SIBN SiBone	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/6/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/6/2025	SIBN SiBone	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/30/2025	SRDX Surmodics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANGO AngioDynamics	$283.32M	1.36	$4.21 per share	2.25	$5.13 per share	1.85
INO Inovio Pharmaceuticals	$283.10K	180.07	N/A	N/A	$1.90 per share	0.73
SIBN SiBone	$167.18M	4.79	N/A	N/A	$3.98 per share	4.72
SRDX Surmodics	$126.08M	3.52	$0.31 per share	99.68	$8.33 per share	3.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANGO AngioDynamics	-$184.35M	-$1.01	N/A	N/A	N/A	-14.61%	-3.73%	-2.43%	7/15/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
SIBN SiBone	-$30.91M	-$0.64	N/A	N/A	N/A	-15.03%	-16.00%	-11.69%	8/4/2025 (Estimated)
SRDX Surmodics	-$11.54M	-$1.39	N/A	38.78	N/A	-16.34%	-7.10%	-4.77%	7/30/2025 (Estimated)

Latest ANGO, SIBN, INO, and SRDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	SIBN SiBone	-$0.19	N/A	N/A	N/A	$48.12 million	N/A
7/30/2025	Q3 2025	SRDX Surmodics	-$0.21	N/A	N/A	N/A	$28.04 million	N/A
7/15/2025	Q4 2025	ANGO AngioDynamics	-$0.13	N/A	N/A	N/A	$74.26 million	N/A
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/5/2025	Q1 2025	SIBN SiBone	-$0.24	-$0.15	+$0.09	-$0.15	$45.13 million	$47.29 million
4/30/2025	Q2 2025	SRDX Surmodics	-$0.06	-$0.13	-$0.07	-$0.36	$32.23 million	$28.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANGO AngioDynamics	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A
SRDX Surmodics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANGO AngioDynamics	N/A	2.21	1.40
INO Inovio Pharmaceuticals	N/A	2.63	2.63
SIBN SiBone	0.21	8.53	7.26
SRDX Surmodics	0.27	5.14	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANGO AngioDynamics	89.43%
INO Inovio Pharmaceuticals	26.79%
SIBN SiBone	98.11%
SRDX Surmodics	96.63%

Insider Ownership

Company	Insider Ownership
ANGO AngioDynamics	5.40%
INO Inovio Pharmaceuticals	2.30%
SIBN SiBone	4.00%
SRDX Surmodics	8.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANGO AngioDynamics	760	40.61 million	38.41 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
SIBN SiBone	350	42.62 million	40.91 million	Optionable
SRDX Surmodics	450	14.30 million	13.03 million	Optionable

ANGO, SIBN, INO, and SRDX Headlines

Recent News About These Companies

Surmodics, Inc. (SRDX) stock price, news, quote & history - Yahoo Finance

July 3, 2025 | au.finance.yahoo.com

FY2025 EPS Estimates for Surmodics Reduced by Zacks Research

July 3, 2025 | marketbeat.com

Q1 Earnings Estimate for Surmodics Issued By Zacks Research

July 3, 2025 | americanbankingnews.com

Zacks Research Has Bearish Outlook for Surmodics Q1 Earnings

July 2, 2025 | marketbeat.com

QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?

June 6, 2025 | msn.com

Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

May 30, 2025 | zacks.com

Surmodics, Ballinasloe, offers production operator opportunities

May 15, 2025 | advertiser.ieA

Are Options Traders Betting on a Big Move in Surmodics Stock?

May 2, 2025 | msn.com

SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

May 1, 2025 | zacks.com

Surmodics stock takes another hit on Q2 miss and 2025 guidance

April 30, 2025 | massdevice.com

SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

April 30, 2025 | zacks.com

SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates

April 30, 2025 | zacks.com

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

April 30, 2025 | businesswire.com

A Look at Surmodics's Upcoming Earnings Report

April 30, 2025 | benzinga.com

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

April 28, 2025 | businesswire.com

Results Published From TRANSCEND Study of Surmodics SurVeil DCB

April 23, 2025 | evtoday.comE

Surmodics publishes TRANSCEND trial data

April 22, 2025 | markets.businessinsider.com

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

April 22, 2025 | businesswire.com

Illinois joins FTC suit to block GTCR’s takeover of Surmodics

April 17, 2025 | chicagobusiness.comC

AG Ellison Joins Suit to Block Surmodics Acquisition

April 17, 2025 | tcbmag.comT

Barrington Sticks to Their Hold Rating for SurModics (SRDX)

April 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Correction Equals Opportunity in Domino’s Pizza Stock
By Gabriel Osorio-Mazilli | July 6, 2025
View Correction Equals Opportunity in Domino’s Pizza Stock

ANGO, SIBN, INO, and SRDX Company Descriptions

AngioDynamics NASDAQ:ANGO

$9.48 -0.16 (-1.66%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$9.43 -0.05 (-0.53%)

As of 07:00 AM Eastern

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

Inovio Pharmaceuticals NASDAQ:INO

$1.39 -0.06 (-4.14%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.43%)

As of 07:42 AM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

SiBone NASDAQ:SIBN

$18.78 +0.34 (+1.84%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$18.34 -0.44 (-2.32%)

As of 06:12 AM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Surmodics NASDAQ:SRDX

$31.02 +0.18 (+0.58%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$31.02 0.00 (-0.02%)

As of 07/10/2025 04:20 PM Eastern

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time